v3.26.3
Segment Information - Schedule of Segment Information about Segments Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting, Descriptive Information [Abstract]                
Collaboration revenue $ 0     $ 99     $ 0 $ 2,976
Research and development expenses associated with preclinical and clinical studies 28,145 [1]     14,363 [1]     70,693 47,576 [1]
Facilities and related expenses, excluding depreciation and amortization 2,404 [2]     3,595 [2]     7,864 14,882 [2]
General and corporate expenses 2,773 [3]     2,510 [3]     9,166 12,787 [3]
Personnel-related expenses, excluding stock-based compensation 11,122     9,897     32,609 36,072
Other segment items 8,615 [4]     5,196 [4]     23,777 6,791 [4]
Segment net loss $ 53,059 $ 52,788 $ 38,262 $ 35,462 $ 41,235 $ 38,435 $ 144,109 $ 115,132
[1] Research and development expenses associated with preclinical and clinical studies includes research software, professional services and laboratory operations supporting the Company’s research and development programs.
[2] Facilities and related expenses includes rent, common area maintenance costs, repairs and maintenance, utilities, real estate taxes, and the ROU impairment charge.
[3] General and corporate expenses include general and administrative costs associated with professional and consulting fees and other overhead costs.
[4] For the three and nine months ended September 30, 2026 and 2025, other segment items consist of interest income, stock-based compensation expense, depreciation and amortization expense, change in fair value of contingent consideration expense, income tax (benefit) provision and other (income) expense, net. Interest income consists of interest income earned on cash equivalents and marketable securities. Interest expense consists of interest expense on finance leases. Other (income) expense, net primarily consists of realized and unrealized gains and losses on marketable securities.